.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Predict branded drug patent expiration
  • Uncover prior art in abandoned patent applications and expired patents

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

SARAFEM Drug Profile

« Back to Dashboard

Which patents cover Sarafem, and what substitute generic drugs are available?

Sarafem is a drug marketed by Eli Lilly And Co and Apil and is included in two NDAs.

The generic ingredient in SARAFEM is fluoxetine hydrochloride. There are twenty-seven drug master file entries for this compound. Sixty-eight suppliers are listed for this compound. Additional details are available on the fluoxetine hydrochloride profile page.

Summary for Tradename: SARAFEM

Patents:0
Applicants:2
NDAs:2
Suppliers / Packagers: see list3
Bulk Api Vendors: see list83
Patent Applications: see list3,088
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:SARAFEM at DailyMed

Pharmacology for Tradename: SARAFEM

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eli Lilly And Co
SARAFEM
fluoxetine hydrochloride
CAPSULE;ORAL018936-007Jul 6, 2000DISCNYesNo► Subscribe► Subscribe
Apil
SARAFEM
fluoxetine hydrochloride
TABLET;ORAL021860-002May 19, 2006RXYesNo► Subscribe► Subscribe
Eli Lilly And Co
SARAFEM
fluoxetine hydrochloride
CAPSULE;ORAL018936-008Jul 6, 2000DISCNYesNo► Subscribe► Subscribe
Apil
SARAFEM
fluoxetine hydrochloride
TABLET;ORAL021860-001May 19, 2006RXYesNo► Subscribe► Subscribe
Apil
SARAFEM
fluoxetine hydrochloride
TABLET;ORAL021860-003May 19, 2006RXYesYes► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: SARAFEM

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Eli Lilly And Co
SARAFEM
fluoxetine hydrochloride
CAPSULE;ORAL018936-007Jul 6, 20004,971,998*PED► Subscribe
Eli Lilly And Co
SARAFEM
fluoxetine hydrochloride
CAPSULE;ORAL018936-008Jul 6, 20005,744,501*PED► Subscribe
Eli Lilly And Co
SARAFEM
fluoxetine hydrochloride
CAPSULE;ORAL018936-007Jul 6, 20005,114,976*PED► Subscribe
Eli Lilly And Co
SARAFEM
fluoxetine hydrochloride
CAPSULE;ORAL018936-008Jul 6, 20005,114,976*PED► Subscribe
Eli Lilly And Co
SARAFEM
fluoxetine hydrochloride
CAPSULE;ORAL018936-008Jul 6, 20004,971,998*PED► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc